InflaRx NV reports results for the quarter ended June 30 - Earnings Summary

• InflaRx NV IFRX reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of seven analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -21 cents to -10 cents per share.

• Reported revenue was zero​; analysts expected €50.17 thousand.

• InflaRx NV's reported EPS for the quarter was a loss of 21 cents​.

• The company reported a quarterly loss of €14.42 million.

• InflaRx NV shares had risen by 6.3% this quarter and lost 66.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 13.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for InflaRx NV is $3.00, about 72% above its last closing price of $0.84

This summary was machine generated from LSEG data August 7 at 05:08 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)